To Rescue or Not to Rescue Your Study: How to Spot Trigger Points in Strategic Partnerships
Instability is woven into our industry’s DNA. We operate daily in a high-stakes, high-risk environment where financial pressures, regulatory changes, and patient lives hang in the balance. The CRO selection process reflects this tension, few other sectors require competitors to both challenge and collaborate with one another, often for the same client. Our ecosystem is […]
Evidence Matters: Joel White of Marketcap Consultants
Recently, Aaron Berger, SVP of Evidence Development Solutions, had a chance to sit down and talk with Joel White of Marketcap consultants, to discuss the state of life science trends and the next wave of real world evidence generation. Joel has long been an important voice in the life sciences space, always with his finger […]
Rethinking Decentralization in Direct-to-Patient Studies: A Conversation with Aaron Berger
Explore how UBC is leading the transformation of clinical research through decentralized, direct-to-patient study designs. In this interview, Aaron Berger shares insights on improving patient access, data quality, and trial efficiency through UBC’s Evidence Development Solutions.
Beyond Enrollment Woes: Why Sponsors Seek Rescue in Tumultuous Times
Rescue studies are a challenge, and often enrollment is a top reason for switching. But mismatched partnerships go beyond enrollment.
Regulatory Submissions with Real-World Evidence: Highlights from the Joint Duke Margolis Institute and FDA Public Meeting
As Real World Evidence (RWE) continues to shape regulatory decision-making, the FDA and Duke Margolis Institute convened a public meeting to share successes, challenges, and lessons learned in RWE submissions. With over 4,000 attendees, the event spotlighted case studies, data feasibility, and the evolving role of RWE in labeling, post-marketing commitments, and registrational trials. Learn how sponsors are partnering with regulators to modernize study design and advance global RWE standards.
Optimizing REMS Pharmacy Integration: RAPID – UBC’s Standards-Based Solution That Minimizes Burden while Elevating Compliance and Patient Safety
Pharmacies are essential to REMS—but manual processes and fragmented systems create risk and inefficiency. UBC’s RAPID API offers a secure, standards-based integration that streamlines REMS activities directly within pharmacy workflows. Learn how RAPID reduces burden, improves data quality, and elevates patient safety across the REMS ecosystem.
Is Your Real-World Data ‘Fit-for-Purpose’? The Critical Role of Feasibility Assessments
Designing a database study can be challenging with the proliferation of RWD availability and source diversity. Learn how to ensure that database feasibility assessments successfully identify the most relevant data sources appropriate for the evaluation of study objectives.
Enhancing patient engagement with technology and digital solutions
Patient engagement plays a central role in medication adherence, persistence, and retention. Explore how digital tools, including EHRs, electronic healthcare technology, and digital assistants, can contribute meaningfully to patient engagement.
What Place for Humans in a PV World Integrating AI?
Artificial intelligence is transforming pharmacovigilance—but human expertise remains essential. As AI systems evolve to support drug safety monitoring, ensuring human oversight is key to managing risk, improving outcomes, and maintaining trust. At UBC, we’re blending AI innovation with deep PV knowledge, empowering our teams through AI awareness training and shaping a safer future for patients. Discover how AI and humans can work together to advance pharmacovigilance.
